Impaired Angiogenesis in Systemic Sclerosis: The Emerging Role of the Antiangiogenic VEGF165b Splice Variant

Trends in Cardiovascular Medicine

Volumn 21, Issue 7, 2011, Pages 204-210

  Manetti, Mirko ^a   Guiducci, Serena ^b   Ibba Manneschi, Lidia ^a   Matucci Cerinic, Marco ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

UNCLASSIFIED DRUG; VASCULOTROPIN 165; VASCULOTROPIN 165B; VASCULOTROPIN A;

ALTERNATIVE RNA SPLICING; ANGIOGENESIS; AUTOIMMUNITY; FINGER ULCER; GANGRENE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SKIN CAPILLARY; SYSTEMIC SCLEROSIS;

AUTOIMMUNITY; FIBROSIS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; RNA, MESSENGER; SCLERODERMA, SYSTEMIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84864572676     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2012.05.011     Document Type: Review

References (63)

1. Afkhami F., Durocher Y., Prakash S. Investigation of antiangiogenic tumor therapy potential of microencapsulated HEK293 VEGF165b producing cells. J Biomed Biotechnol 2010, 2010:645610.
2. Artac R.A., McFee R.M., Smith R.A., et al. Neutralization of vascular endothelial growth factor antiangiogenic isoforms is more effective than treatment with proangiogenic isoforms in stimulating vascular development and follicle progression in the perinatal rat ovary. Biol Reprod 2009, 81:978-988.
3. Ballmer-Hofer K., Andersson A.E., Ratcliffe L.E., Berger P. Neuropilin-1 promotes VEGFR-2 trafficking through Rab11 vesicles thereby specifying signal output. Blood 2011, 118:816-826.
4. Baltes-Breitwisch M.M., Artac R.A., Bott R.C., et al. Neutralization of vascular endothelial growth factor antiangiogenic isoforms or administration of proangiogenic isoforms stimulates vascular development in the rat testis. Reproduction 2010, 140:319-329.
5. Bates D.O., Cui T.G., Doughty J.M., et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is downregulated in renal cell carcinoma. Cancer Res 2002, 62:4123-4131.
6. Bates D.O., MacMillan P.P., Manjaly J.G., et al. The endogenous antiangiogenic family of splice variants of VEGF, VEGFxxxb, are downregulated in preeclamptic placentae at term. Clin Sci (Lond) 2006, 110:575-585.
7. Bevan H.S., van den Akker N.M., Qiu Y., et al. The alternatively spliced antiangiogenic family of VEGF isoforms, VEGFxxxb, in human kidney development. Nephron Physiol 2008, 110:57-67.
8. Bielecki M., Kowal K., Lapinska A., et al. Peripheral blood mononuclear cells from patients with systemic sclerosis spontaneously secrete increased amounts of vascular endothelial growth factor (VEGF) already in the early stage of the disease. Adv Med Sci 2011, 56:255-263.
9. Bills V.L., Varet J., Millar A., et al. Failure to up-regulate VEGF165b in maternal plasma is a first trimester predictive marker for pre-eclampsia. Clin Sci (Lond) 2009, 116:265-272.
10. Byrne A.M., Bouchier-Hayes D.J., Harmey J.H. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 2005, 9:777-794.
11. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000, 6:389-395.
12. Carvalho J.F., Blank M., Shoenfeld Y. Vascular endothelial growth factor (VEGF) in autoimmune diseases. J Clin Immunol 2007, 27:246-256.
13. Cébe Suarez S., Pieren M., Cariolato L., et al. A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell Mol Life Sci 2006, 63:2067-2077.
14. Choi J.J., Min D.J., Cho M.L., et al. Elevated vascular endothelial growth factor in systemic sclerosis. J Rheumatol 2003, 30:1529-1533.
15. Davies C.A., Jeziorska M., Freemont A.J., Herrick A.L. The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. Hum Pathol 2006, 37:190-197.
16. Díaz R., Peña C., Silva J., et al. p73 isoforms affect VEGF, VEGF165b and PEDF expression in human colorectal tumors: VEGF165b downregulation as a marker of poor prognosis. Int J Cancer 2008, 123:1060-1067.
17. Distler O., Del Rosso A., Giacomelli R., et al. Angiogenic and angiostatic factors in systemic sclerosis: Increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 2002, 4:R11.
18. Distler O., Distler J.H., Scheid A., et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 2004, 95:109-116.
19. Dokun A.O., Annex B.H. The VEGF165b "ICE-o-form" puts a chill on the VEGF story. Circ Res 2011, 109:246-247.
20. Ergorul C., Ray A., Huang W., et al. Levels of vascular endothelial growth factor-A165b (VEGF-A165b) are elevated in experimental glaucoma. Mol Vis 2008, 14:1517-1524.
21. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 2005, 94:209-231.
22. Ferrara N., Carver-Moore K., Chen H., et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996, 380:439-442.
23. Ferrara N., Henzel W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989, 161:851-858.
24. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1:27-31.
25. Gabrielli A., Avvedimento E.V., Krieg T. Scleroderma. N Engl J Med 2009, 360:1989-2003.
26. Geyer M., Müller-Ladner U. The pathogenesis of systemic sclerosis revisited. Clin Rev Allergy Immunol 2011, 40:92-103.
27. Guiducci S., Giacomelli R., Cerinic M.M. Vascular complications of scleroderma. Autoimmun Rev 2007, 6:520-523.
28. Hagiwara M. Alternative splicing: A new drug target of the post-genome era. Biochim Biophys Acta 2005, 1754:324-331.
29. Harper S.J., Bates D.O. VEGF-A splicing: The key to anti-angiogenic therapeutics?. Nat Rev Cancer 2008, 8:880-887.
30. Hinchcliff M., Desai C.S., Varga J., Shah S.J. Prevalence, prognosis, and factors associated with left ventricular diastolic dysfunction in systemic sclerosis. Clin Exp Rheumatol 2012, 30:S30-S37.
31. Hua J., Spee C., Kase S., et al. Recombinant human VEGF165b inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2010, 51:4282-4288.
32. Hummers L.K., Hall A., Wigley F.M., Simons M. Abnormalities in the regulators of angiogenesis in patients with scleroderma. J Rheumatol 2009, 36:576-582.
33. Kahaleh B. Vascular disease in scleroderma: Mechanisms of vascular injury. Rheum Dis Clin North Am 2008, 34:57-71.
34. Kawamura H., Li X., Harper S.J., et al. Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity. Cancer Res 2008, 68:4683-4692.
35. Konopatskaya O., Churchill A.J., Harper S.J., et al. VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice. Mol Vis 2006, 12:626-632.
36. Kuryliszyn-Moskal A., Klimiuk P.A., Sierakowski S. Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: Relationship to organ systemic involvement. Clin Rheumatol 2005, 24:111-116.
37. LeRoy E.C. Systemic sclerosis: A vascular perspective. Rheum Dis Clin North Am 1996, 22:675-694.
38. Mackiewicz Z., Sukura A., Povilenaité D., et al. Increased but imbalanced expression of VEGF and its receptors has no positive effect on angiogenesis in systemic sclerosis skin. Clin Exp Rheumatol 2002, 20:641-646.
39. Magnussen A.L., Rennel E.S., Hua J., et al. VEGF-A165b is cytoprotective and antiangiogenic in the retina. Invest Ophthalmol Vis Sci 2010, 51:4273-4281.
40. Manetti M., Guiducci S., Ibba-Manneschi L., Matucci-Cerinic M. Mechanisms in the loss of capillaries in systemic sclerosis: Angiogenesis versus vasculogenesis. J Cell Mol Med 2010, 14:1241-1254.
41. Manetti M., Guiducci S., Romano E., et al. Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis. Circ Res 2011, 109:e14-e26.
42. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999, 13:9-22.
43. Neufeld G., Cohen T., Gitay-Goren H., et al. Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants. Cancer Metastasis Rev 1996, 15:153-158.
44. Nihtyanova S.I., Brough G.M., Black C.M., Denton C.P. Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2008, 67:120-123.
45. Nowak D.G., Woolard J., Amin E.M., et al. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J Cell Sci 2008, 121:3487-3495.
46. Olsson A.K., Dimberg A., Kreuger J., Claesson-Welsh L. VEGF receptor signalling-In control of vascular function. Nat Rev Mol Cell Biol 2006, 7:359-371.
47. Ong V.H., Denton C.P. Innovative therapies for systemic sclerosis. Curr Opin Rheumatol 2010, 22:264-272.
48. Peiris-Pagès M., Harper S.J., Bates D.O., Ramani P. Balance of pro- versus anti-angiogenic splice isoforms of vascular endothelial growth factor as a regulator of neuroblastoma growth. J Pathol 2010, 222:138-147.
49. Perrin R.M., Konopatskaya O., Qiu Y., et al. Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia 2005, 48:2422-2427.
50. Pritchard-Jones R.O., Dunn D.B., Qiu Y., et al. Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma. Br J Cancer 2007, 97:223-230.
51. Qiu Y., Bevan H., Weeraperuma S., et al. Mammary alveolar development during lactation is inhibited by the endogenous antiangiogenic growth factor isoform, VEGF165b. FASEB J 2008, 22:1104-1112.
52. Qiu Y., Hoareau-Aveilla C., Oltean S., et al. The antiangiogenic isoforms of VEGF in health and disease. Biochem Soc Trans 2009, 37:1207-1213.
53. Rabquer B.J., Koch A.E. Angiogenesis and vasculopathy in systemic sclerosis: Evolving concepts. Curr Rheumatol Rep 2012, 14:56-63.
54. Rennel E., Waine E., Guan H., et al. The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. Br J Cancer 2008, 98:1250-1257.
55. Rennel E.S., Harper S.J., Bates D.O. Therapeutic potential of manipulating VEGF splice isoforms in oncology. Future Oncol 2009, 5:703-712.
56. Ricker L.J., Dieudonné S.C., Kessels A.G., et al. Antiangiogenic isoforms of vascular endothelial growth factor predominate in subretinal fluid of patients with rhegmatogenous retinal detachment and proliferative vitreoretinopathy. Retina 2012, 32:54-59.
57. Schumacher V.A., Jeruschke S., Eitner F., et al. Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome. J Am Soc Nephrol 2007, 18:719-729.
58. Senger D.R., Galli S.J., Dvorak A.M., et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-985.
59. Solanilla A., Villeneuve J., Auguste P., et al. The transport of high amounts of vascular endothelial growth factor by blood platelets underlines their potential contribution in systemic sclerosis angiogenesis. Rheumatology 2009, 48:1036-1044.
60. Steen V.D., Medsger T.A. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007, 66:940-944.
61. Varey A.H., Rennel E.S., Qiu Y., et al. VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: Balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. Br J Cancer 2008, 98:1366-1379.
62. Varga J., Abraham D. Systemic sclerosis: A prototypic multisystem fibrotic disorder. J Clin Invest 2007, 117:557-567.
63. Woolard J., Wang W.Y., Bevan H.S., et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: Mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 2004, 64:7822-7835.